Sempra Declares Common and Preferred Dividends


Oxford malaria vaccine data bodes well for effort to combat deadly disease

Encouraging new data on a malaria vaccine from Oxford University bodes well for global effort to combat the mosquito-borne disease that kills a child every minute, its makers said on Wednesday. After decades of work, the only approved malaria vaccine, Mosquirix, made by British drugmaker GSK, was recently endorsed by the World Health Organization (WHO). Oxford’s vaccine, called R21/Matrix-M, is likely more effective than Mosquirix in preventing the disease that kills about 600,000 a year despite roughly $3 billion spent annually on insecticides, bednets and anti-malarial drugs, Oxford scientist Adrian Hill said.

Leave a Reply

Your email address will not be published.